The Latest Updates
Egret Therapeutics Announces Appointment Ron Cohen, M.D. to its Board of Directors
Egret Therapeutics, a portfolio company of Turret Capital Management, is a clinical stage biotechnology company focused on function preservation post acute ischemic injury NEW YORK, Sept. 4, 2024 /PRNewswire/ --…
Read More
Sable Therapeutics Announces Exclusive Worldwide Licensing Agreement with Columbia University to Develop Novel Polycation Nanomedicines for the Treatment of Obesity
Sable Therapeutics, a portfolio company of Turret Capital Management, announces licensing agreement with Columbia University NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Sable Therapeutics, an innovative early stage drug development company focused on…
Read More
Terran Biosciences Announces Development of TerXT
Terran Biosciences Announces Development of TerXT, a Combination of Xanomeline and Trospium Prodrugs for the Treatment of Schizophrenia, and Intends to Pursue Accelerated 505(b)(2) Approval Pathway May 20, 2024 08:30…
Read More
Baudax Bio Acquires TeraImmune, Inc.
TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood…
Read More
Sable Therapeutics Announces Licensing Agreement with Shanghai Liuqiang Medical Technology Co.
For Development and Commercial Rights to its Fat Reducing SBL-003/SBL-004 Microneedle Patch in Greater China. Sable Therapeutics, a portfolio company of Turret Capital Management, announces licensing agreement for Greater China NEW…
Read More
Egret Therapeutics Receives FDA Clearance of IND Application for EGT 101 for Treatment of Delayed Cerebral Ischemia
Egret Therapeutics, a portfolio company of Turret Capital Management, announces FDA Clearance of its IND Application for EGT 101 NEW YORK, Feb. 4, 2023 /PRNewswire/ -- Egret Therapeutics, a clinical-stage biotechnology company…
Read More
Egret Therapeutics Announces the Addition of Three New Members to its Scientific Advisory Board
Egret Therapeutics, a portfolio company of Turret Capital Management, Announces the Addition of Three New Members. NEW YORK, Jan. 3, 2023 /PRNewswire/ -- Egret Therapeutics, a clinical-stage company focused on the treatment…
Read More
Egret Therapeutics completes oversubscribed pre-A financing round
NEW YORK, Feb. 15, 2022 /PRNewswire/ -- Egret Therapeutics, a clinical-stage biotherapeutics company focused on the treatment of neurological diseases, announced today the completion of its pre-A financing. The funding was led by…
Read More
Turret Capital Announces Dr. Mary Lake Polan To Join Board Of Directors Of Koi Therapeutics
NEW YORK, Jan. 15, 2021 /PRNewswire/ -- Turret Capital Management announced today that Dr. Mary Lake Polan has been appointed to the Board of Directors of its subsidiary company, Koi Therapeutics. Mary Lake Polan,…
Read More
Turret Capital announces a global in-licensing agreement with Genexine
NEW YORK, Jan. 19, 2021 /PRNewswire/ -- Turret Capital Management, a global investment and venture building firm focused on the healthcare industry, announced today that it has signed a Definitive License Agreement with…
Read More
Turret Capital Management and Or-Genix Therapeutics Establish Strategic Partnership
NEW YORK, June 29, 2020 /PRNewswire/ -- Turret Capital Management, a global venture building and investment firm focused on the healthcare industry, has signed a Definitive License Agreement with Or-Genix Therapeutics, Inc. Under the…
Read More
Milu Labs and Thermo Fisher Scientific Announce Collaboration MOU to Advance the expansion of “Women’s Health products” in the China market
NEW YORK, Oct. 23, 2019 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, and Milu Labs., whose mission is to become the leading diagnostic and analysis company focused on cutting edge…
Read More
